{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:01Z","timestamp":1793047201520,"version":"4.5.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40291-026-00872-3","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:41:36Z","timestamp":1788788496000},"page":"999-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anbalcabtagene Autoleucel: First Approval"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"9","key":"872_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"2","key":"872_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bjh.18797","volume":"202","author":"S Lamure","year":"2023","unstructured":"Lamure S, Herbaux C. Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL. Br J Haematol. 2023;202(2):217\u20138.","journal-title":"Br J Haematol"},{"key":"872_CR3","unstructured":"ProBio, Curocell Inc. ProBio and Curocell achieve key CAR-T milestone with BLA regulatory approval and commercial readiness [media release]. 11 May 2026. http:\/\/www.probiocdmo.com."},{"key":"872_CR4","unstructured":"South Korea Ministry of Food and Drug Safety. MFDS approves first domestically developed CAR-T gene therapy [media release]. 4 May 2026. https:\/\/nedrug.mfds.go.kr\/bbs\/119\/1372\/."},{"key":"872_CR5","unstructured":"Curocell Inc. Curocell drug development pipeline. 2023. https:\/\/curocellbtx.com\/sciences\/. Accessed 27 May 2026."},{"key":"872_CR6","unstructured":"Curocell Inc. Anbalcabtagene autoleucel (RIMQARTO): South Korean prescribing information [machine translated]. 2026. https:\/\/health.kr\/searchDrug\/result_drug.asp?drug_cd=2026043000010. Accessed 5 May 2026."},{"issue":"2","key":"872_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee YH, Lee HJ, Kim HC, et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022;30(2):579\u201392.","journal-title":"Mol Ther"},{"key":"872_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032636","author":"WS Kim","year":"2026","unstructured":"Kim WS, Kim SJ, Yoon DH, et al. Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed\/refractory large B-cell lymphoma (CRC01-01). Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032636.","journal-title":"Blood"},{"key":"872_CR9","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.276","author":"HJ Seo","year":"2025","unstructured":"Seo HJ, Yoo WH, Jung K, et al. Comparative effectiveness of anbalcabtagene autoleucel versus tisagenlecleucel in patients with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Res Treat. 2025. https:\/\/doi.org\/10.4143\/crt.2025.276.","journal-title":"Cancer Res Treat"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00872-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:04:15Z","timestamp":1793045055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00872-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00872-3","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}